LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

Search

Guardant Health Inc

Închisă

SectorSănătate

93.98 -4.02

Rezumat

Modificarea prețului

24h

Curent

Minim

93.29

Maxim

97.92

Indicatori cheie

By Trading Economics

Venit

7.2M

-93M

Vânzări

33M

265M

Marjă de profit

-34.965

Angajați

1,999

EBITDA

6.6M

-82M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

-10.06% downside

Statistici piață

By TradingEconomics

Capitalizare de piață

3.3B

12B

Deschiderea anterioară

98

Închiderea anterioară

93.98

Sentimentul știrilor

By Acuity

50%

50%

171 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Guardant Health Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

13 nov. 2025, 21:34 UTC

Câștiguri

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

13 nov. 2025, 23:45 UTC

Market Talk

Nikkei May Fall After Wall Street's Weakness -- Market Talk

13 nov. 2025, 23:42 UTC

Achiziții, Fuziuni, Preluări

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

13 nov. 2025, 23:41 UTC

Market Talk

Gold Edges Higher on Possible Dip-Buying -- Market Talk

13 nov. 2025, 23:24 UTC

Câștiguri

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

13 nov. 2025, 23:24 UTC

Câștiguri

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

13 nov. 2025, 23:23 UTC

Câștiguri

JBS NV 3Q EPS 52c >JBS

13 nov. 2025, 23:23 UTC

Câștiguri

JBS NV 3Q Sales $22.6B >JBS

13 nov. 2025, 23:04 UTC

Market Talk

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

13 nov. 2025, 22:02 UTC

Câștiguri

Nu Holdings 3Q Net $783M >NU

13 nov. 2025, 22:01 UTC

Câștiguri

Nu Holdings 3Q Rev $4.2B >NU

13 nov. 2025, 21:51 UTC

Achiziții, Fuziuni, Preluări

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

13 nov. 2025, 21:50 UTC

Câștiguri

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

13 nov. 2025, 21:45 UTC

Achiziții, Fuziuni, Preluări

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

13 nov. 2025, 21:41 UTC

Achiziții, Fuziuni, Preluări

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

13 nov. 2025, 21:36 UTC

Achiziții, Fuziuni, Preluări

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

13 nov. 2025, 21:36 UTC

Achiziții, Fuziuni, Preluări

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

13 nov. 2025, 21:36 UTC

Achiziții, Fuziuni, Preluări

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

13 nov. 2025, 21:36 UTC

Achiziții, Fuziuni, Preluări

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

13 nov. 2025, 21:36 UTC

Achiziții, Fuziuni, Preluări

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

13 nov. 2025, 21:33 UTC

Market Talk

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

13 nov. 2025, 21:33 UTC

Câștiguri

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

13 nov. 2025, 21:31 UTC

Câștiguri

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

13 nov. 2025, 21:25 UTC

Câștiguri

Figure Tech Solutions 3Q Rev $156.4M >FIGR

13 nov. 2025, 21:25 UTC

Câștiguri

Figure Tech Solutions 3Q EPS 34c >FIGR

13 nov. 2025, 21:23 UTC

Câștiguri

Intchains Group 3Q Rev $1.3M >ICG

13 nov. 2025, 21:03 UTC

Câștiguri

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

13 nov. 2025, 21:02 UTC

Câștiguri

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

13 nov. 2025, 21:01 UTC

Câștiguri

Applied Materials 4Q Rev $6.8B >AMAT

13 nov. 2025, 21:01 UTC

Câștiguri

Applied Materials 4Q Gross Margin 48.0% >AMAT

Comparație

Modificare preț

Guardant Health Inc Așteptări

Obiectiv de preț

By TipRanks

-10.06% jos

Prognoză pe 12 luni

Medie 88 USD  -10.06%

Maxim 120 USD

Minim 60 USD

În baza a 21 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruGuardant Health Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

21 ratings

21

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

38.86 / 47.41Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

171 / 374 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat